Barclays’s Aptevo Therapeutics APVO Stock Holding History

Barclays’s Portfolio APVO Stock Details APVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$138	Buy	+31	New	+$149	﹤0.01%	5159
2022 Q3	–	Hold	0	–	-$283K	–	4772
2022 Q2	–	Hold	0	–	–	–	3231
2022 Q1	–	Hold	0	–	–	–	3052
2018 Q4	–	Hold	0	–	-$105K	–	6905
2018 Q3	–	Hold	0	–	–	–	5493
2018 Q2	–	Hold	0	–	–	–	5220
2018 Q1	–	Hold	0	–	–	–	5662
2017 Q4	–	Hold	0	–	–	–	5347
2017 Q3	–	Hold	0	–	–	–	6825
2017 Q2	–	Hold	0	–	–	–	6616
2017 Q1	–	Hold	0	–	–	–	5719
2016 Q4	–	Hold	0	–	–	–	6587
2016 Q3	–	Hold	0	–	–	–	6585

Other funds holding APVO

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Barclays's APVO Position: Q2 2026 in Review

Barclays opened a new position in Aptevo Therapeutics (APVO) in Q2 2026: 31 shares worth $138. The stake represents ﹤0.01% of the portfolio and ranks #5159 among its holdings.

9 funds tracked by Wall St. Rank hold APVO as of Q2 2026.

Barclays held 31 shares of Aptevo Therapeutics worth $138 as of Q2 2026.
Aptevo Therapeutics was a new Barclays position in Q2 2026.
Aptevo Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5159 holding.
9 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.